Serum and urinary biomarkers for detection and active surveillance of prostate cancer

Maria F. Becerra, Abhishek Bhat, Ali Mouzannar, Venkatasai S. Atluri, Sanoj Punnen

Research output: Contribution to journalReview article

Abstract

Purpose of review To provide a comprehensive review of the available biomarkers for the detection and active surveillance of prostate cancer and simplify decision-making while choosing between them. Recent findings The limitations of PSA and mpMRI and the invasive nature of prostate biopsy has led to a constant search for serum and urinary biomarkers for both the detection and monitoring during active surveillance of prostate cancer. 4K, PHI and PCA3 have been validated in prospective clinical trials for initial detection of prostate cancer and recent evidence points to potential differentiation between indolent and aggressive cancer. However, the usage in monitoring tumor dynamics is debatable because of lack of conclusive evidence. The answer to the existing problems lies in high-quality studies to establish definitive evidence and also to help choose between the plethora of biomarkers available today. Summary Despite the advancements in innovation and usage of biomarkers in prostate cancer, there exists tremendous potential in improving them to fulfil the unmet need that exists today. Studies to establish conclusive evidence and integration with imaging can tremendously aid diagnosis and monitoring.

Original languageEnglish (US)
JournalCurrent opinion in urology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Prostatic Neoplasms
Biomarkers
Serum
Prostate
Neoplasms
Decision Making
Clinical Trials
Biopsy

Keywords

  • active surveillance
  • clinically significant cancer
  • prostate cancer
  • serum biomarkers
  • urine biomarkers

ASJC Scopus subject areas

  • Urology

Cite this

Serum and urinary biomarkers for detection and active surveillance of prostate cancer. / Becerra, Maria F.; Bhat, Abhishek; Mouzannar, Ali; Atluri, Venkatasai S.; Punnen, Sanoj.

In: Current opinion in urology, 01.01.2019.

Research output: Contribution to journalReview article

Becerra, Maria F. ; Bhat, Abhishek ; Mouzannar, Ali ; Atluri, Venkatasai S. ; Punnen, Sanoj. / Serum and urinary biomarkers for detection and active surveillance of prostate cancer. In: Current opinion in urology. 2019.
@article{bceab457be21457381df71da8c6ea1bc,
title = "Serum and urinary biomarkers for detection and active surveillance of prostate cancer",
abstract = "Purpose of review To provide a comprehensive review of the available biomarkers for the detection and active surveillance of prostate cancer and simplify decision-making while choosing between them. Recent findings The limitations of PSA and mpMRI and the invasive nature of prostate biopsy has led to a constant search for serum and urinary biomarkers for both the detection and monitoring during active surveillance of prostate cancer. 4K, PHI and PCA3 have been validated in prospective clinical trials for initial detection of prostate cancer and recent evidence points to potential differentiation between indolent and aggressive cancer. However, the usage in monitoring tumor dynamics is debatable because of lack of conclusive evidence. The answer to the existing problems lies in high-quality studies to establish definitive evidence and also to help choose between the plethora of biomarkers available today. Summary Despite the advancements in innovation and usage of biomarkers in prostate cancer, there exists tremendous potential in improving them to fulfil the unmet need that exists today. Studies to establish conclusive evidence and integration with imaging can tremendously aid diagnosis and monitoring.",
keywords = "active surveillance, clinically significant cancer, prostate cancer, serum biomarkers, urine biomarkers",
author = "Becerra, {Maria F.} and Abhishek Bhat and Ali Mouzannar and Atluri, {Venkatasai S.} and Sanoj Punnen",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/MOU.0000000000000670",
language = "English (US)",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Serum and urinary biomarkers for detection and active surveillance of prostate cancer

AU - Becerra, Maria F.

AU - Bhat, Abhishek

AU - Mouzannar, Ali

AU - Atluri, Venkatasai S.

AU - Punnen, Sanoj

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose of review To provide a comprehensive review of the available biomarkers for the detection and active surveillance of prostate cancer and simplify decision-making while choosing between them. Recent findings The limitations of PSA and mpMRI and the invasive nature of prostate biopsy has led to a constant search for serum and urinary biomarkers for both the detection and monitoring during active surveillance of prostate cancer. 4K, PHI and PCA3 have been validated in prospective clinical trials for initial detection of prostate cancer and recent evidence points to potential differentiation between indolent and aggressive cancer. However, the usage in monitoring tumor dynamics is debatable because of lack of conclusive evidence. The answer to the existing problems lies in high-quality studies to establish definitive evidence and also to help choose between the plethora of biomarkers available today. Summary Despite the advancements in innovation and usage of biomarkers in prostate cancer, there exists tremendous potential in improving them to fulfil the unmet need that exists today. Studies to establish conclusive evidence and integration with imaging can tremendously aid diagnosis and monitoring.

AB - Purpose of review To provide a comprehensive review of the available biomarkers for the detection and active surveillance of prostate cancer and simplify decision-making while choosing between them. Recent findings The limitations of PSA and mpMRI and the invasive nature of prostate biopsy has led to a constant search for serum and urinary biomarkers for both the detection and monitoring during active surveillance of prostate cancer. 4K, PHI and PCA3 have been validated in prospective clinical trials for initial detection of prostate cancer and recent evidence points to potential differentiation between indolent and aggressive cancer. However, the usage in monitoring tumor dynamics is debatable because of lack of conclusive evidence. The answer to the existing problems lies in high-quality studies to establish definitive evidence and also to help choose between the plethora of biomarkers available today. Summary Despite the advancements in innovation and usage of biomarkers in prostate cancer, there exists tremendous potential in improving them to fulfil the unmet need that exists today. Studies to establish conclusive evidence and integration with imaging can tremendously aid diagnosis and monitoring.

KW - active surveillance

KW - clinically significant cancer

KW - prostate cancer

KW - serum biomarkers

KW - urine biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85071500919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071500919&partnerID=8YFLogxK

U2 - 10.1097/MOU.0000000000000670

DO - 10.1097/MOU.0000000000000670

M3 - Review article

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

ER -